For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Mazdutide
Weight & Metabolicphase_2_3

Mazdutide

IBI362
Weight & Metabolic · CAS 2259884-03-0
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Weight & Metabolic
Evidence grade
B
PubMed records
46
Female-tagged
8
Sex-analysis
0
CAS
2259884-03-0
B
Evidence grade B, Phase 2/3 human trial evidence across 46 indexed studies (mixed-sex). How grades work →
Female evidence: Extrapolated
Mazdutide: of 46 PubMed records, 8 are tagged as including female subjects and 0 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Mazdutide is a synthetic dual-agonist peptide based on the gut hormone oxyntomodulin, engineered to activate both the GLP-1 and glucagon receptors. It is a 39-residue lipidated peptide whose combined receptor pharmacology gives it a distinctive profile as a tool compound in metabolic and incretin research.

In vitro and in preclinical systems, mazdutide has been studied for its dual receptor engagement and the way GLP-1 and glucagon signaling interact within energy-balance pathways. Researchers examining metabolism have used it as a research material to characterize effects on glucose-handling and lipid-metabolism signaling and on energy-expenditure mechanisms.

What makes mazdutide notable for a metabolic catalog is its position among multi-receptor incretin analogues, where the balance between two pathways is itself the object of study. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

Mazdutide is a GLP-1/glucagon dual-receptor agonist based on oxyntomodulin, developed for obesity and type 2 diabetes. It has advanced through late-stage trials and was recently approved in China, though it remains investigational in most markets; trials enrolled women but did not report sex-specific analyses.

Evidence in women

Menstrual cycle
Unstudied
No study examined weight or glycemic response across the menstrual cycle.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data; incretin agonists are generally avoided in pregnancy.
Hormonal interactions
Unstudied
Delayed gastric emptying could in theory affect oral contraceptive absorption, but this has not been studied for mazdutide.
Perimenopause & menopause
Unstudied
No perimenopause- or menopause-specific efficacy or safety analyses.
Sex differences
Unstudied
Trials enrolled women but published results were not analyzed by sex.

Mechanism

A synthetic oxyntomodulin analog that co-activates GLP-1 and glucagon receptors, combining appetite suppression with increased energy expenditure.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Up to ~9 mg subcutaneous weekly in late-stage obesity trials; recently approved in China, investigational elsewhere.
Routessubcutaneous
Female-specific dosingNot established

Contraindications: personal or family history of medullary thyroid carcinoma or MEN2 (incretin class effect, theoretical)

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

nauseavomitingdiarrheadecreased appetite

Mazdutide reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Mazdutide

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Mazdutide's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Mazdutide?

Mazdutide, also known as IBI362, is a research compound in our weight metabolic category. Mazdutide is a GLP-1/glucagon dual-receptor agonist based on oxyntomodulin, developed for obesity and type 2 diabetes.

Is Mazdutide studied in women?

Mazdutide: of 46 PubMed records, 8 are tagged as including female subjects and 0 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has Mazdutide been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data; incretin agonists are generally avoided in pregnancy. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Mazdutide have, and why?

Mazdutide carries evidence grade B. Phase 2/3 human trial evidence across 46 indexed studies (mixed-sex).. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Mazdutide?

No. A female-specific dose for Mazdutide is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Mazdutide administered in research?

In the published literature, Mazdutide is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Mazdutide?

Effects reported in the research literature include nausea, vomiting, diarrhea, decreased appetite. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

What is the CAS number for Mazdutide?

The CAS registry number for Mazdutide is 2259884-03-0. It is also referred to as IBI362, LY3305677. Use it to confirm identity against a Certificate of Analysis.

How should Mazdutide be stored and handled?

Mazdutide sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Mazdutide for research?

For laboratory research use, Mazdutide is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy Mazdutide at Aurevena Research
Research-use supplier: Mazdutide is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Citations (PMID)

39305981 · 41054801

Related peptides

4X Blend (Methionine / Choline / Carnitine / Dexpanthenol)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
5-Amino-1MQD
5-Amino-1MQ: of 3 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.
8X Blend (L-Carnitine / L-Arginine / Methionine / Inositol / Choline / B6 / B5 / B12)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
AdipotideD
Adipotide: of 4 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.